- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07947966
Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of REGN20566 in Adult Participants With Overweight or Obesity
This study will test a Regeneron drug called REGN20566 ("study drug") to see how safe it is and how participants with overweight or obesity respond to it.
The study will be split into two parts, Part A and Part B.
The study is looking at:
- What side effects REGN20566 might cause
- How much REGN20566 is in the blood at different times
- If the body reacts to REGN20566 in a way that may cause REGN20566 to not work as well
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Total planned duration of trial participation for each participant (excluding screening period):
- Part A: approximately 16 weeks
- Part B: approximately 27 weeks
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-post: clinicaltrials@regeneron.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Has a body mass index 27-40 kg/m2, inclusive, at screening visit or prior to randomization
- Healthy volunteers with obesity
Key Exclusion Criteria:
- A self-reported change of body weight >5 kg within 90 days of screening visit
- History of type 1 or 2 diabetes, or bariatric surgery
- Hemoglobin A1c (HbA1c) ≥6.5% at the screening visit
- History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease
- Received a nutrient stimulating hormone (NuSH)-based therapy (eg, Glucagon-like peptide-1 receptor agonist [GLP-1RA]) within 6 months of the screening visit
- Planned initiation of NuSH-based therapy, bariatric surgery, or alternative procedures aimed at reducing weight or altering of body composition during the duration of the trial
- Received an anti-obesity medication within 90 days of screening visit
Note: Other protocol defined Inclusion/ Exclusion Criteria apply
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Del A
|
Administered per the protocol Administered per the protocol |
|
Placebo-jämförare: Part B
|
Administered per the protocol Administered per the protocol |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Tidsram: Up to 16 weeks
|
Part A |
Up to 16 weeks
|
|
Severity of TEAEs
Tidsram: Up to 16 weeks
|
Part A |
Up to 16 weeks
|
|
Occurrence of TEAEs
Tidsram: Up to 27 weeks
|
Part B |
Up to 27 weeks
|
|
Severity of TEAEs
Tidsram: Up to 27 weeks
|
Part B |
Up to 27 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Concentration of REGN20566 in serum
Tidsram: Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Concentration of REGN20566 in serum
Tidsram: Baseline through week 27
|
Part B |
Baseline through week 27
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN20566
Tidsram: Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Magnitude of ADA to REGN20566
Tidsram: Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Occurrence of ADA to REGN20566
Tidsram: Baseline through week 27
|
Part B |
Baseline through week 27
|
|
Magnitude of ADA to REGN20566
Tidsram: Baseline through week 27
|
Part B |
Baseline through week 27
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Trial Management, Regeneron Pharmaceuticals
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- R20566-OB-2626
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Tidsram för IPD-delning
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Kriterier för IPD Sharing Access
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- ANALYTIC_CODE
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .